Newtyn Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Newtyn Management’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-200,000	Closed	-$5.02M	–	36
2025 Q1	$5.02M	Sell	200,000 -70,000	-26%	-$1.77M	0.79%	24
2024 Q4	$7.42M	Sell	270,000 -230,000	-46%	-$6.41M	1.29%	23
2024 Q3	$14.4M	Hold	500,000	–	–	2.21%	16
2024 Q2	$12.4M	Buy	500,000 +134,000	+37%	+$3.8M	2.33%	15
2024 Q1	$11.8M	Buy	366,000 +147,913	+68%	+$5.5M	2.35%	15
2023 Q4	$8.87M	Sell	218,087 -56,913	-21%	-$2.09M	1.74%	19
2023 Q3	$9.5M	Buy	275,000 +5,000	+2%	+$195K	2.34%	14
2023 Q2	$11M	Buy	270,000 +1,718	+0.6%	+$70.1K	2.59%	14
2023 Q1	$10.4M	Buy	268,282 +13,282	+5%	+$546K	2.04%	18
2022 Q4	$11.3M	Buy	255,000 +75,000	+42%	+$3.16M	2.34%	16
2022 Q3	$7.67M	Buy	180,000 +10,000	+6%	+$512K	1.69%	21
2022 Q2	$9.49M	Buy	170,000 +56,600	+50%	+$3.36M	1.8%	20
2022 Q1	$7.03M	Buy	+113,400	New	+$6.94M	1.68%	23

Other funds holding LKFT

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Newtyn Management's LKFT Position: Q2 2025 in Review

Newtyn Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2025, closing a stake of 200,000 shares — an estimated $5.02M sold.

Newtyn Management first reported a position in LKFT in Q1 2022 and held it in 13 quarters. The position peaked at $14.4M in Q3 2024. 85 funds tracked by Wall St. Rank hold LKFT as of Q2 2025.

Newtyn Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2025 after selling out during the quarter.
Newtyn Management sold 200,000 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2025, an estimated $5.02M.
Newtyn Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2022 and held it in 13 quarters.
Newtyn Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $14.4M in Q3 2024.
85 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2025.

Based on Newtyn Management's 13F filing for Q2 2025, filed 14 Aug 2025.